Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Therapy Area Introduction
2.1.1 Alzheimer’s Disease
2.1.2 Parkinson’s Disease
2.1.3 Multiple Sclerosis
2.1.4 Huntington’s Disease
2.1.5 Amyotrophic Lateral Sclerosis
2.2 Symptoms
2.3 Diagnosis
2.3.1 Alzheimer’s Disease
2.3.2 Parkinson’s Disease
2.3.3 Multiple Sclerosis
2.3.4 Huntington’s Disease
2.3.5 Amyotrophic Lateral Sclerosis
2.4 Etiology and Pathophysiology
2.4.1 Alzheimer’s Disease
2.4.2 Parkinson’s Disease
2.4.3 Multiple Sclerosis
2.4.4 Huntington’s Disease
2.4.5 Amyotrophic Lateral Sclerosis
2.5 Epidemiology
2.5.1 Alzheimer’s Disease
2.5.2 Parkinson’s Disease
2.5.3 Multiple Sclerosis
2.5.4 Huntington’s Disease
2.5.5 Amyotrophic Lateral Sclerosis
2.6 Prognosis and Disease Staging
2.6.1 Alzheimer’s Disease
2.6.2 Parkinson’s Disease
2.6.3 Multiple Sclerosis
2.6.4 Huntington’s Disease
2.6.5 Amyotrophic Lateral Sclerosis
2.7 Treatment
2.7.1 Alzheimer’s Disease
2.7.2 Parkinson’s Disease
2.7.3 Multiple Sclerosis
2.7.4 Huntington’s Disease
2.7.5 Amyotrophic Lateral Sclerosis
3 Key Marketed Products
3.1 Overview
3.2 Current and Future Trends in the MS Market
3.3 Copaxone (glatiramer acetate) – Teva
3.4 Tecfidera (dimethyl fumarate) – Biogen
3.5 Gilenya (fingolimod) – Novartis
3.6 Avonex (Interferon beta-1a) – Biogen
3.7 Tysabri (natalizumab) – Biogen
3.8 Ocrevus (ocrelizumab) – F. Hoffmann-La Roche Ltd.
3.9 Namenda/Ebixa/Axura/Abixa Memary (memantine hydrochloride) – Merz/Lundbeck/Forest/Daiichi/ Sankyo
3.10 Aricept (donepezil) – Eisai/Pfizer
3.11 Azilect (rasagiline mesylate) –Teva
3.12 Neupro (rotigotine) – UCB
3.13 Radicut (edaravone) – Mitsubishi Tanabe Pharma Corp
3.14 Xenazine (tetrabenazine) – Valeant Pharmaceuticals International Inc.
3.15 Spinraza (nusinersen) – Biogen
4 Pipeline Landscape Assessment
4.1 Overview
4.2 Pipeline Development Landscape
4.2.1 Neurodegenerative Disease Overall
4.2.2 Key Neurodegenerative Disease Indications
4.3 Molecular Targets in the Pipeline
4.3.1 Neurodegenerative Disease Overall
4.3.2 Key Neurodegenerative Disease Indications
4.4 Clinical Trials
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecular Type and Molecular Target
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecular Type and Molecular Target
4.5 Assessment of Key Pipeline Products
4.5.1 Aducanumab – Biogen/Eisai
4.5.2 Azeliragon – vTv Therapeutics
4.5.3 ChariSMA – AveXis
4.5.4 Omaveloxolone – Reata Pharmaceuticals
4.5.5 Siponimod – Novartis
4.5.6 Ozanimod – Celgene
4.5.7 Elenbecestat – Eisai
4.5.8 BAN-2401 – Sage Therapeutics
4.5.9 IONIS-HTTRx
4.6 Conclusion
5 Multi-scenario Market Forecast to 2023
5.1 Overall Market Size
5.2 Generic Penetration
5.3 Revenue Forecast by Molecular Target
5.3.1 Neuromodulators
5.3.2 Immunomodulators
5.3.3 Stress-related Targets
5.3.4 Protein Misfolding Targets
5.3.5 Neuroprotectants
6 Company Analysis and Positioning
6.1 Revenue and Market Share Analysis by Company
6.1.1 Biogen – Aducanumab and Tecfidera Cement Biogen as the Market Leader
6.1.2 Roche – Increasing Sales of Ocrevus to Drive Market Size
6.1.3 Novartis – Gradual Decline in Revenue due to Gilenya Patent Expiration Offset by Large Pipeline
6.1.4 Teva – Gradual Decline in Revenue due to Patent Expiration of Premium Product Copaxone
6.1.5 Eisai – Elenbecestat and BAN-2401 Driving New Market Growth for Eisai
6.1.6 Sanofi – Aubagio and Lemtrada on Course for Blockbuster Status in 2023
6.2 Company Landscape
6.3 Marketed and Pipeline Portfolio Analysis
6.3.1 Conclusion
7 Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deals by Region, Year and Value
7.1.2 Deals by Indication
7.1.3 Deals by Stage of Development and Value
7.1.4 Deals by Molecule Type and Molecular Target
7.1.5 Table for Licensing Deals Valued Above $100m
7.2 Co-development Deals
7.2.1 Deals by Region, Year and Value
7.2.2 Deals by Indication
7.2.3 Deals by Stage of Development and Value
7.2.4 Deals by Molecule Type, Mechanism of Action and Value
7.2.5 Table for Co-development Deals Valued Above $100m
8 Appendix
8.1 Bibliography
8.2 All Pipeline Drugs by Phase
8.2.1 Discovery
8.2.2 Preclinical
8.2.3 IND/CTA-Filed/Phase 0
8.2.4 Phase I
8.2.5 Phase II
8.2.6 Phase III
8.2.7 Pre-registration
8.3 Abbreviations
8.4 Disease List
8.4.1 Alzheimer’s disease
8.4.2 Parkinson’s disease
8.4.3 Multiple sclerosis
8.4.4 Amyotrophic lateral sclerosis
8.4.5 Huntington’s disease
8.4.6 Other
8.5 Methodology
8.5.1 Coverage
8.5.2 Secondary Research
8.5.3 Market Size and Revenue Forecasts
8.5.4 Pipeline Analysis
8.5.5 Competitive Landscape
8.6 Contact Us
8.7 Disclaimer